|
|
|
Volumn 52, Issue 9 SUPPL., 1992, Pages
|
|
The clinical evaluation of cancer chemoprevention agents: Defining and contrasting phase I, II, and III objectives
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BETA CAROTENE;
PROSTAGLANDIN SYNTHASE INHIBITOR;
RETINOID;
RETINOL;
SELENIUM;
CANCER PREVENTION;
CANCER RESEARCH;
CANCER RISK;
CLINICAL PHARMACOLOGY;
CONFERENCE PAPER;
HUMAN;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
SAMPLING;
SIDE EFFECT;
ANTICARCINOGENIC AGENTS;
CLINICAL TRIALS;
DRUG EVALUATION;
HUMAN;
|
|
EID: 0026747888
PISSN: 00085472
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (43)
|
|
References (0)
|
